Maze Therapeutics (MAZE) Director Nancy Andrews Receives Award

What Happened Nancy C. Andrews, a director of Maze Therapeutics, was granted a derivative award on 2026-06-08 for 18,000 shares (reported at $0.00). The filing classifies this as an award/grant (derivative), meaning Andrews did not pay cash for the grant; it is an option-like award that could convert into shares subject to vesting and exercise.

Key Details

• Transaction date: June 8, 2026; Form 4 filed June 10, 2026 (appears timely).
• Transaction type/code: A = Award/Grant (derivative); acquisition price reported as $0.00.
• Shares/units granted: 18,000 (derivative position).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The option vests and becomes fully exercisable on the earlier of the issuer’s 2027 annual meeting or June 8, 2027, subject to Andrews’ continued service.
• No indication of a 10b5-1 plan, tax-withholding sale, or immediate cashless exercise in the provided details.

Context This was a compensation grant (option-like award) to a director, not an open-market purchase or sale. Such grants are routine for executive and board compensation and represent potential future shares only after vesting and any required exercise; they do not necessarily signal immediate buying or selling by the insider.